These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

97 related articles for article (PubMed ID: 229809)

  • 1. Peripheral neuropathy secondary to cis-Dichlorodiammino-platinum (II) (Platinol). Treatment for advanced ovarian cancer.
    Marin AC; Rierson B
    Ariz Med; 1979 Dec; 36(12):898-9. PubMed ID: 229809
    [No Abstract]   [Full Text] [Related]  

  • 2. cis-Dichlorodiammineplatinum(II) for the treatment of advanced ovarian cancer.
    Young RC; Von Hoff DD; Gormley P; Makuch R; Cassidy J; Howser D; Bull JM
    Cancer Treat Rep; 1979; 63(9-10):1539-44. PubMed ID: 387224
    [TBL] [Abstract][Full Text] [Related]  

  • 3. High-dose (200 mg/m2) cisplatin-induced neurotoxicity in primary advanced ovarian cancer patients.
    Panici PB; Greggi S; Scambia G; Di Roberto P; Iacobelli S; Mancuso S
    Cancer Treat Rep; 1987 Jun; 71(6):669-70. PubMed ID: 3034424
    [No Abstract]   [Full Text] [Related]  

  • 4. Psychometric evaluation of two scales assessing functional status and peripheral neuropathy associated with chemotherapy for ovarian cancer: a gynecologic oncology group study.
    Almadrones L; McGuire DB; Walczak JR; Florio CM; Tian C
    Oncol Nurs Forum; 2004 May; 31(3):615-23. PubMed ID: 15146227
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Single-agent cis-platinum therapy for advanced ovarian cancer.
    Gershenson DM; Wharton JT; Herson J; Edwards CL; Rutledge FN
    Obstet Gynecol; 1981 Oct; 58(4):487-96. PubMed ID: 7024883
    [TBL] [Abstract][Full Text] [Related]  

  • 6. cis-Dichlorodiammineplatinum(II) as third-line chemotherapy in advanced ovarian adenocarcinoma.
    Piver MS; Barlow JJ; Lele SB; Higby DJ
    Cancer Treat Rep; 1978 Apr; 62(4):559-60. PubMed ID: 350393
    [No Abstract]   [Full Text] [Related]  

  • 7. High-dose cisplatin-related peripheral neuropathy.
    Ostchega Y; Donohue M; Fox N
    Cancer Nurs; 1988 Feb; 11(1):23-32. PubMed ID: 2834044
    [No Abstract]   [Full Text] [Related]  

  • 8. Treatment of advanced ovarian cancer with cis=dichlorodiammineplatinum(II): poor-risk patients with intensive prior therapy.
    Bruckner HW; Cohen CJ; Wallach RC; Kabakow B; Deppe G; Greenspan EM; Gusberg SB; Holland JF
    Cancer Treat Rep; 1978 Apr; 62(4):555-8. PubMed ID: 350392
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cis-dichlorodiammine platinum (II) in advanced ovarian carcinoma.
    Stewart JF; Tattersall MH; Woods RL; Fox RM
    Med J Aust; 1979 Jun; 1(12):548-50. PubMed ID: 470725
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Cis-platinum-induced peripheral neuropathy. One case (author's transl)].
    Gastaut JL; Pellissier JF; Jean P; Tubiana N; Carcassonne Y
    Nouv Presse Med; 1982 Apr; 11(15):1113-7. PubMed ID: 6281722
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Cisplatin polyneuropathy].
    Beghi E; Bogliun G; Crespi V; Delodovici ML; Landoni F
    Riv Neurobiol; 1984; 30(2-3):431-7. PubMed ID: 6100526
    [No Abstract]   [Full Text] [Related]  

  • 12. [Cis-platinum (DDP) in the treatment of advanced malignant ovarian tumors--report of 30 cases].
    Liu LY
    Zhonghua Zhong Liu Za Zhi; 1983 Nov; 5(6):433-6. PubMed ID: 6687118
    [No Abstract]   [Full Text] [Related]  

  • 13. Reproductive and sexual function after platinum-based chemotherapy in long-term ovarian germ cell tumor survivors: a Gynecologic Oncology Group Study.
    Gershenson DM; Miller AM; Champion VL; Monahan PO; Zhao Q; Cella D; Williams SD;
    J Clin Oncol; 2007 Jul; 25(19):2792-7. PubMed ID: 17602084
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Limits to the "benefits" from our oncologic interventions: a case report.
    Markman M
    Gynecol Oncol; 2000 Aug; 78(2):261-2. PubMed ID: 10926815
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Paclitaxel in platinum-resistant ovarian cancer patients. Argentine Multicenter Taxol Group.
    Ezcurdia L; Jovtis SL; Mickiewicz E; Temperley G; Rondinón M; Blajman C; Cóppola FS; Lewi D; Cazap E; Breier S; Fasce H; Fein L; Polera J; Triguboff E; Uranga G; Pasccón G; Luchina AM; Martínez CA; Politi PM; Rubio G; Alvarez AM
    Semin Oncol; 1997 Oct; 24(5 Suppl 15):S15-53-S15-56. PubMed ID: 9346223
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Dose-escalated paclitaxel in 1-hour infusion with a fixed dose of cisplatin in previously untreated advanced ovarian cancer: a phase II trial of the Spanish Group for Ovarian Cancer.
    Cervantes A; Mendiola C; del Campo JM; Massuti B; Casado A; Escobedo A; Moyano A; Ojeda B; Poveda A; Benito D
    Semin Oncol; 1997 Oct; 24(5 Suppl 15):S15-40-S15-43. PubMed ID: 9346221
    [TBL] [Abstract][Full Text] [Related]  

  • 17. High-dose cisplatin carboplatin chemotherapy in primary advanced epithelial ovarian cancer.
    Fanning J; Hilgers RD
    Gynecol Oncol; 1993 Nov; 51(2):182-6. PubMed ID: 8276291
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Treatment of gynecological cancer with cis-platinum].
    Mano T; Takeshima N; Nakamura Y; Tomimatsu T; Saito T; Miyake T
    Gan To Kagaku Ryoho; 1987 Oct; 14(10):2895-9. PubMed ID: 3662545
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cancer of the ovary: a summary of experience with cis-dichlorodiammineplatinum(II) at the Royal Marsden Hospital.
    Wiltshaw E; Subramarian S; Alexopoulos C; Barker GH
    Cancer Treat Rep; 1979; 63(9-10):1545-8. PubMed ID: 387225
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Tumor chemotherapy of ovarian cancer patients in advanced age].
    Behling H; Schirmer A; Krafft W; Brückmann D
    Zentralbl Gynakol; 1988; 110(2):95-101. PubMed ID: 3364065
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.